Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Non-antibiotic Treatment Modalities for Bacterial Vaginosis

Author(s): Sarah Adelia, Athaya Ardelia and Devi Artami Susetiati*

Volume 24, Issue 2, 2024

Published on: 20 October, 2023

Article ID: e201023222451 Pages: 11

DOI: 10.2174/0118715265250557231011065142

Price: $65

Abstract

Caused by an imbalance in the vaginal microbiome, bacterial vaginosis (BV) is among the most commonly occurring vaginal infections in women of childbearing age. If untreated, BV may have a detrimental impact on the obstetric and gynecological health of an individual. To date, treatment for BV includes a regimen of antibiotics and avoidance of relevant risk factors. Since recurrence and reinfection are frequently observed in patients, pharmaceutical treatment for BV remains ineffective nevertheless. Repeated exposure to antibiotics could precipitate drug-resistant strains. The severity of this problem leads to the emergence of non-antimicrobial therapies. This article aims to provide a review on the types and efficacy of various alternative, non-antimicrobial therapeutic regimens.

Graphical Abstract

[1]
Holmes, K.K.; Sparling, P.; Piot, P.; Wasserheit, J.N.; Wasserheit, J.; Corey, L.; Cohen, M. Sexually Transmitted Diseases, 4th ed; McGraw-Hill Professional, 2008.
[2]
Kenyon, C.; Colebunders, R.; Crucitti, T. The global epidemiology of bacterial vaginosis: A systematic review. Am. J. Obstet. Gynecol., 2013, 209(6), 505-523.
[http://dx.doi.org/10.1016/j.ajog.2013.05.006] [PMID: 23659989]
[3]
Pal, K.; Kumar, N.; Behera, B.; Sagiri, S.S.; Ray, S.; Roy, S. Bacterial vaginosis: Etiology and modalities of treatment-A brief note. J. Pharm. Bioallied Sci., 2011, 3(4), 496-503.
[http://dx.doi.org/10.4103/0975-7406.90102] [PMID: 22219582]
[4]
Bautista, C.T.; Wurapa, E.; Sateren, W.B.; Morris, S.; Hollingsworth, B.; Sanchez, J.L. Bacterial vaginosis: A synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil. Med. Res., 2016, 3(1), 4.
[http://dx.doi.org/10.1186/s40779-016-0074-5] [PMID: 26877884]
[5]
Abou Chacra, L.; Fenollar, F.; Diop, K. Bacterial vaginosis: What do we currently know? Front. Cell. Infect. Microbiol., 2022, 11, 672429.
[http://dx.doi.org/10.3389/fcimb.2021.672429] [PMID: 35118003]
[6]
Amabebe, E.; Anumba, D.O.C. The vaginal microenvironment: The physiologic role of lactobacilli. Front. Med., 2018, 5, 181.
[http://dx.doi.org/10.3389/fmed.2018.00181] [PMID: 29951482]
[7]
Muzny, C.A.; Sobel, J.D. The role of antimicrobial resistance in refractory and recurrent bacterial vaginosis and current recommendations for treatment. Antibiotics, 2022, 11(4), 500.
[http://dx.doi.org/10.3390/antibiotics11040500] [PMID: 35453251]
[8]
Vodstrcil, L.A.; Muzny, C.A.; Plummer, E.L.; Sobel, J.D.; Bradshaw, C.S. Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment. BMC Med., 2021, 19(1), 194.
[http://dx.doi.org/10.1186/s12916-021-02077-3] [PMID: 34470644]
[9]
Chen, X.; Lu, Y.; Chen, T.; Li, R. The female vaginal microbiome in health and bacterial vaginosis. Front. Cell. Infect. Microbiol., 2021, 11, 631972.
[http://dx.doi.org/10.3389/fcimb.2021.631972] [PMID: 33898328]
[10]
Pekmezovic, M.; Mogavero, S.; Naglik, J.R.; Hube, B. Host–Pathogen Interactions during Female Genital Tract Infections. Trends Microbiol., 2019, 27(12), 982-996.
[http://dx.doi.org/10.1016/j.tim.2019.07.006] [PMID: 31451347]
[11]
Tachedjian, G.; Aldunate, M.; Bradshaw, C.S.; Cone, R.A. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res. Microbiol., 2017, 168(9-10), 782-792.
[http://dx.doi.org/10.1016/j.resmic.2017.04.001] [PMID: 28435139]
[12]
Joseph, R.J.; Ser, H.L.; Kuai, Y.H.; Tan, L.T.H.; Arasoo, V.J.T.; Letchumanan, V.; Wang, L.; Pusparajah, P.; Goh, B.H.; Ab Mutalib, N.S.; Chan, K.G.; Lee, L.H. Finding a balance in the vaginal microbiome: How do we treat and prevent the occurrence of bacterial vaginosis? Antibiotics, 2021, 10(6), 719.
[http://dx.doi.org/10.3390/antibiotics10060719] [PMID: 34203908]
[13]
Laue, C.; Papazova, E.; Liesegang, A.; Pannenbeckers, A.; Arendarski, P.; Linnerth, B.; Domig, K.J.; Kneifel, W.; Petricevic, L.; Schrezenmeir, J. Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women – a double-blind, randomised, controlled clinical pilot trial. Benef. Microbes, 2018, 9(1), 35-50.
[http://dx.doi.org/10.3920/BM2017.0018] [PMID: 29065710]
[14]
Wu, S; Hugerth, LW; Schuppe-Koistinen, I; Du, J The right bug in the right place: Opportunities for bacterial vaginosis treatment. NPJ Biofilms Microbiomes., 2022, 8(1)
[http://dx.doi.org/10.1038/s41522-022-00295-y]
[15]
Ravel, J.; Gajer, P.; Abdo, Z.; Schneider, G.M.; Koenig, S.S.K.; McCulle, S.L.; Karlebach, S.; Gorle, R.; Russell, J.; Tacket, C.O.; Brotman, R.M.; Davis, C.C.; Ault, K.; Peralta, L.; Forney, L.J. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci., 2011, 108(S1), 4680-4687.
[http://dx.doi.org/10.1073/pnas.1002611107] [PMID: 20534435]
[16]
Smith, S.B.; Ravel, J. The vaginal microbiota, host defence and reproductive physiology. J. Physiol., 2017, 595(2), 451-463.
[http://dx.doi.org/10.1113/JP271694] [PMID: 27373840]
[17]
Ranjit, E.; Raghubanshi, B.R.; Maskey, S.; Parajuli, P. Prevalence of bacterial vaginosis and its association with risk factors among nonpregnant women: A hospital based study. Int. J. Microbiol., 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/8349601] [PMID: 29692813]
[18]
Javed, A.; Parvaiz, F.; Manzoor, S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it’s associated resistance patterns. Microb. Pathog., 2019, 127, 21-30.
[http://dx.doi.org/10.1016/j.micpath.2018.11.046] [PMID: 30502515]
[19]
Brotman, R.M.; Klebanoff, M.A.; Nansel, T.R.; Andrews, W.W.; Schwebke, J.R.; Zhang, J.; Yu, K.F.; Zenilman, J.M.; Scharfstein, D.O. A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am. J. Epidemiol., 2008, 168(2), 188-196.
[http://dx.doi.org/10.1093/aje/kwn103] [PMID: 18503038]
[20]
Amsel, R.; Totten, P.A.; Spiegel, C.A.; Chen, K.C.S.; Eschenbach, D.; Holmes, K.K. Nonspecific vaginitis. Am. J. Med., 1983, 74(1), 14-22.
[http://dx.doi.org/10.1016/0002-9343(83)91112-9] [PMID: 6600371]
[21]
Nugent, R.P.; Krohn, M.A.; Hillier, S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J. Clin. Microbiol., 1991, 29(2), 297-301.
[http://dx.doi.org/10.1128/jcm.29.2.297-301.1991] [PMID: 1706728]
[22]
Onderdonk, A.B.; Delaney, M.L.; Fichorova, R.N. The human microbiome during bacterial vaginosis. Clin. Microbiol. Rev., 2016, 29(2), 223-238.
[http://dx.doi.org/10.1128/CMR.00075-15] [PMID: 26864580]
[23]
Menard, J.P. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int. J. Womens Health, 2011, 3, 295-305.
[http://dx.doi.org/10.2147/IJWH.S23814] [PMID: 21976983]
[24]
Tomás, M.; Palmeira-de-Oliveira, A.; Simões, S.; Martinez-de-Oliveira, J.; Palmeira-de-Oliveira, R. Bacterial vaginosis: Standard treatments and alternative strategies. Int. J. Pharm., 2020, 587, 119659.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119659] [PMID: 32687973]
[25]
Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections: CDC Treatment Guidelines 2021; U.S. Department of Health and Human Services, 2021.
[26]
Chen, R.; Li, R.; Qing, W.; Zhang, Y.; Zhou, Z.; Hou, Y.; Shi, Y.; Zhou, H.; Chen, M. Probiotics are a good choice for the treatment of bacterial vaginosis: A meta-analysis of randomized controlled trial. Reprod. Health, 2022, 19(1), 137.
[http://dx.doi.org/10.1186/s12978-022-01449-z] [PMID: 35698149]
[27]
Mastromarino, P.; Vitali, B.; Mosca, L. Bacterial vaginosis: A review on clinical trials with probiotics. New Microbiol., 2013, 36(3), 229-238.
[PMID: 23912864]
[28]
Cribby, S.; Taylor, M.; Reid, G. Vaginal microbiota and the use of probiotics. Interdiscip. Perspect. Infect. Dis., 2008, 2008, 1-9.
[http://dx.doi.org/10.1155/2008/256490] [PMID: 19343185]
[29]
Han, Y.; Ren, Q. Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis. Curr. Opin. Pharmacol., 2021, 61, 83-90.
[http://dx.doi.org/10.1016/j.coph.2021.09.004] [PMID: 34649216]
[30]
Reznichenko, H.; Henyk, N.; Maliuk, V.; Khyzhnyak, T.; Tynna, Y.; Filipiuk, I.; Veresniuk, N.; Zubrytska, L.; Quintens, J.; Richir, K.; Gerasymov, S. Oral intake of lactobacilli can be helpful in symptomatic bacterial vaginosis: A randomized clinical study. J. Low. Genit. Tract Dis., 2020, 24(3), 284-289.
[http://dx.doi.org/10.1097/LGT.0000000000000518] [PMID: 32091443]
[31]
Happel, A.U.; Kullin, B.; Gamieldien, H.; Wentzel, N.; Zauchenberger, C.Z.; Jaspan, H.B.; Dabee, S.; Barnabas, S.L.; Jaumdally, S.Z.; Dietrich, J.; Gray, G.; Bekker, L.G.; Froissart, R.; Passmore, J.A.S. Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis. PLoS Pathog., 2020, 16(6), e1008559.
[http://dx.doi.org/10.1371/journal.ppat.1008559] [PMID: 32497109]
[32]
Hidayati, A.N.; Widiatma, R.R.; Murtiastutik, D.; Surono, I.S.; Prakoeswa, C.R.S.; Bintanjoyo, L. Effect of Lactobacillus plantarum IS-10506 supplementation with oral metronidazole for the treatment of bacterial vaginosis: A randomized placebo-controlled clinical trial. J. Pak. Assoc. Dermatol., 2022, 32(4), 707-714.
[33]
Vujic, G.; Jajac Knez, A.; Despot Stefanovic, V.; Kuzmic Vrbanovic, V. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: A double-blind, randomized, placebo-controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 168(1), 75-79.
[http://dx.doi.org/10.1016/j.ejogrb.2012.12.031] [PMID: 23395559]
[34]
Martinez, R.C.R.; Franceschini, S.A.; Patta, M.C.; Quintana, S.M.; Gomes, B.C.; De Martinis, E.C.P.; Reid, G. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can. J. Microbiol., 2009, 55(2), 133-138.
[http://dx.doi.org/10.1139/W08-102] [PMID: 19295645]
[35]
Laughton, J.M.; Devillard, E.; Heinrichs, D.E.; Reid, G.; McCormick, J.K. Inhibition of expression of a staphylococcal superantigen-like protein by a soluble factor from Lactobacillus reuteri. Microbiology, 2006, 152(4), 1155-1167.
[http://dx.doi.org/10.1099/mic.0.28654-0] [PMID: 16549678]
[36]
Zhang, Y.; Lyu, J.; Ge, L.; Huang, L.; Peng, Z.; Liang, Y.; Zhang, X.; Fan, S. Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an adjunctive treatment for bacterial vaginosis do not increase the cure rate in a chinese cohort: A prospective, parallel-group, randomized, controlled study. Front. Cell. Infect. Microbiol., 2021, 11, 669901.
[http://dx.doi.org/10.3389/fcimb.2021.669901] [PMID: 34295831]
[37]
Balaghi, Z.; Azima, S.; Motamedifar, M.; Kaviani, M.; Poordast, T.; Zare, N. The effect of lactofem oral probiotic capsule on lactobacilli colonization and some vaginal health parameters. Gynecol. Obstet. Invest., 2020, 85(3), 245-251.
[http://dx.doi.org/10.1159/000506802] [PMID: 32252049]
[38]
Elsharkawy, I.; Noureldin, E.; Mohamed, E.; Mohamed, A.; Abdeldayem, H.; Mansour, S.A.M. Continuous versus interrupted use of vaginal probiotics plus vaginal clindamycin cream for bacterial vaginosis: A randomized controlled study. J. Matern. Fetal Neonatal Med., 2021, 34(1), 58-65.
[http://dx.doi.org/10.1080/14767058.2019.1588246] [PMID: 30879366]
[39]
Bohbot, J.M.; Daraï, E.; Bretelle, F.; Brami, G.; Daniel, C.; Cardot, J.M. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J. Gynecol. Obstet. Hum. Reprod., 2018, 47(2), 81-86.
[http://dx.doi.org/10.1016/j.jogoh.2017.11.005] [PMID: 29196153]
[40]
Hemalatha, R.; Mastromarino, P.; Ramalaxmi, B.A.; Balakrishna, N.V.; Sesikeran, B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: A randomized, double-blind study. Eur. J. Clin. Microbiol. Infect. Dis., 2012, 31(11), 3097-3105.
[http://dx.doi.org/10.1007/s10096-012-1671-1] [PMID: 22777592]
[41]
Armstrong, E.; Hemmerling, A.; Miller, S.; Burke, K.E.; Newmann, S.J.; Morris, S.R.; Reno, H.; Huibner, S.; Kulikova, M.; Nagelkerke, N.; Coburn, B.; Cohen, C.R.; Kaul, R. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: Results from a randomised, placebo-controlled trial. Lancet Microbe, 2022, 3(6), e435-e442.
[http://dx.doi.org/10.1016/S2666-5247(22)00043-X] [PMID: 35659905]
[42]
Ling, Z.; Liu, X.; Chen, W.; Luo, Y.; Yuan, L.; Xia, Y.; Nelson, K.E.; Huang, S.; Zhang, S.; Wang, Y.; Yuan, J.; Li, L.; Xiang, C. The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics. Microb. Ecol., 2013, 65(3), 773-780.
[http://dx.doi.org/10.1007/s00248-012-0154-3] [PMID: 23250116]
[43]
Abbe, C; Mitchell, CM Bacterial vaginosis: A review of approaches to treatment and prevention. Front Reprod Health., 2023, 5, 1100029.
[http://dx.doi.org/10.3389/frph.2023.1100029]
[44]
van Nood, E.; Vrieze, A.; Nieuwdorp, M.; Fuentes, S.; Zoetendal, E.G.; de Vos, W.M.; Visser, C.E.; Kuijper, E.J.; Bartelsman, J.F.W.M.; Tijssen, J.G.P.; Speelman, P.; Dijkgraaf, M.G.W.; Keller, J.J. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med., 2013, 368(5), 407-415.
[http://dx.doi.org/10.1056/NEJMoa1205037] [PMID: 23323867]
[45]
Chen, T.; Xia, C.; Hu, H.; Wang, H.; Tan, B.; Tian, P.; Zhao, X.; Wang, L.; Han, Y.; Deng, K.Y.; Wei, H.; Xin, H.B. Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination. Int. J. Antimicrob. Agents, 2021, 57(3), 106277.
[http://dx.doi.org/10.1016/j.ijantimicag.2021.106277] [PMID: 33434677]
[46]
Lev-Sagie, A.; Goldman-Wohl, D.; Cohen, Y.; Dori-Bachash, M.; Leshem, A.; Mor, U.; Strahilevitz, J.; Moses, A.E.; Shapiro, H.; Yagel, S.; Elinav, E. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat. Med., 2019, 25(10), 1500-1504.
[http://dx.doi.org/10.1038/s41591-019-0600-6] [PMID: 31591599]
[47]
Vieira-Baptista, P.; De Seta, F.; Verstraelen, H.; Ventolini, G.; Lonnee-Hoffmann, R.; Lev-Sagie, A. The vaginal microbiome: V. Therapeutic modalities of vaginal microbiome engineering and research challenges. J. Low. Genit. Tract Dis., 2022, 26(1), 99-104.
[http://dx.doi.org/10.1097/LGT.0000000000000647] [PMID: 34928260]
[48]
Mendling, W.; Shazly, M.A.E.; Zhang, L. The role of lactic acid in the management of bacterial vaginosis: A systematic literature review. Future Pharmacology, 2022, 2(3), 198-213.
[http://dx.doi.org/10.3390/futurepharmacol2030014]
[49]
Tyssen, D.; Hearps, A.C.; Guntur, K.; Masson, L.; Cook, S.; Moulton, S.E.; Ravel, J.; Bradshaw, C.S.; Ayehunie, S.; Tachedjian, G. The impact of over-the-counter lactic acid containing vaginal gels on the integrity and inflammatory state of the vaginal epithelium in vitro. Frontiers in Reproductive Health, 2022, 4, 915948.
[http://dx.doi.org/10.3389/frph.2022.915948] [PMID: 36303665]
[50]
Armstrong-Buisseret, L.; Brittain, C.; Kai, J.; David, M.; Anstey Watkins, J.; Ozolins, M.; Jackson, L.; Abdali, Z.; Hepburn, T.; Griffiths, F.; Montgomery, A.; Daniels, J.; Manley, A.; Dean, G.; Ross, J.D.C. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: The VITA RCT. Health Technol. Assess., 2022, 26(2), 1-170.
[http://dx.doi.org/10.3310/ZZKH4176] [PMID: 35057905]
[51]
Plummer, E.L.; Bradshaw, C.S.; Doyle, M.; Fairley, C.K.; Murray, G.L.; Bateson, D.; Masson, L.; Slifirski, J.; Tachedjian, G.; Vodstrcil, L.A. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. PLoS One, 2021, 16(2), e0246953.
[http://dx.doi.org/10.1371/journal.pone.0246953] [PMID: 33571286]
[52]
Keller, M.J.; Carpenter, C.A.; Lo, Y.; Einstein, M.H.; Liu, C.; Fredricks, D.N.; Herold, B.C. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One, 2012, 7(10), e46901.
[http://dx.doi.org/10.1371/journal.pone.0046901] [PMID: 23056520]
[53]
van der Veer, C.; Bruisten, S.M.; van Houdt, R.; Matser, A.A.; Tachedjian, G.; van de Wijgert, J.H.H.M.; de Vries, H.J.C.; van der Helm, J.J. Effects of an over-the-counter lactic-acid containing intra-vaginal douching product on the vaginal microbiota. BMC Microbiol., 2019, 19(1), 168.
[http://dx.doi.org/10.1186/s12866-019-1545-0] [PMID: 31345159]
[54]
O’Hanlon, D.E.; Moench, T.R.; Cone, R.A. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect. Dis., 2011, 11(1), 200.
[http://dx.doi.org/10.1186/1471-2334-11-200] [PMID: 21771337]
[55]
Khazaeian, S.; Navidian, A.; Navabi-Rigi, S.; Araban, M.; Mojab, F.; Khazaeian, S. Comparing the effect of sucrose gel and metronidazole gel in treatment of clinical symptoms of bacterial vaginosis: A randomized controlled trial. Trials, 2018, 19(1), 585.
[http://dx.doi.org/10.1186/s13063-018-2905-z] [PMID: 30367673]
[56]
Xiao, B.B.; Zhang, D.; Chen, R.; Shi, H.R.; Xin, X.R.; Wang, H.L.; Pang, Y.C.; Zhu, S.N.; Yao, C.; Liao, Q.P. [Sucrose gel for treatment of bacterial vaginosis: A randomized, double-blind, multi-center, parallel-group, phase III clinical trial]. Beijing Da Xue Xue Bao, 2015, 47(6), 925-932.
[PMID: 26679652]
[57]
Hu, K.; Zheng, J.; Yu, Z.; Chen, Z.; Cheng, H.; Pan, W.; Yang, W.; Wang, H.; Deng, Q.; Zeng, Z. Directed shift of vaginal microbiota induced by vaginal application of sucrose gel in rhesus macaques. Int. J. Infect. Dis., 2015, 33, 32-36.
[http://dx.doi.org/10.1016/j.ijid.2014.12.040] [PMID: 25546169]
[58]
Tominaga, K.; Sato, S.; Hayashi, M. Activated charcoal as an effective treatment for bacterial vaginosis. Pers. med. universe., 2012, 1(1), 54-57.
[http://dx.doi.org/10.1016/j.pmu.2012.05.009]
[59]
Kopel, J.; McDonald, J.; Hamood, A. An assessment of the in vitro models and clinical trials related to the antimicrobial activities of phytochemicals. Antibiotics, 2022, 11(12), 1838.
[http://dx.doi.org/10.3390/antibiotics11121838] [PMID: 36551494]
[60]
Murina, F.; Vicariotto, F.; Di Francesco, S. Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. New Microbiol., 2018, 41(3), 220-224.
[PMID: 29874389]
[61]
Abedi, P.; Pazhohideh, Z.; Mohammadi, S.; Bahrami, N.; Mojab, F.; Maraghi, E. The effect of Calendula officinalisversus metronidazole on bacterial vaginosis in women: A double-blind randomized controlled trial. J. Adv. Pharm. Technol. Res., 2018, 9(1), 15-19.
[http://dx.doi.org/10.4103/japtr.JAPTR_305_17] [PMID: 29441319]
[62]
Afzali, E.; siahposh, A.; Haghighi-Zadeh, M.H.; Farajzadeh, A.; Abbaspoor, Z. The effect of Quercus (Oak Gal) vaginal cream versus metronidazole vaginal gel on bacterial vaginosis: A double-blind randomized controlled trial. Complement. Ther. Med., 2020, 52, 102497.
[http://dx.doi.org/10.1016/j.ctim.2020.102497] [PMID: 32951746]
[63]
Askari, S.F.; Jahromi, B.N.; Dehghanian, A.; Zarei, A.; Tansaz, M.; Badr, P.; Azadi, A.; Mohagheghzadeh, A. Effect of a novel herbal vaginal suppository containing myrtle and oak gall in the treatment of vaginitis: A randomized clinical trial. Daru, 2020, 28(2), 603-614.
[http://dx.doi.org/10.1007/s40199-020-00365-6] [PMID: 32888185]
[64]
Abu-Zaid, A.; Alshahrani, M.S.; Bakhsh, H.; Miski, N.T.; Abuzaid, M.; Alomar, O.; Jabrah, E.; Jamjoom, M.Z.; Salem, H.; Al-Badawi, I.A.; Baradwan, S. Astodrimer gel for treatment of bacterial vaginosis: A systematic review and meta-analysis of randomized controlled trials. Int. J. Clin. Pract., 2021, 75(7), e14165.
[http://dx.doi.org/10.1111/ijcp.14165] [PMID: 33749959]
[65]
Mendling, W.; Holzgreve, W. Astodrimer sodium and bacterial vaginosis: A mini review. Arch. Gynecol. Obstet., 2022, 306(1), 101-108.
[http://dx.doi.org/10.1007/s00404-022-06429-z] [PMID: 35246717]
[66]
Chavoustie, S.E.; Carter, B.A.; Waldbaum, A.S.; Donders, G.G.G.; Peters, K.H.; Schwebke, J.R.; Paull, J.R.A.; Price, C.F.; Castellarnau, A.; McCloud, P.; Kinghorn, G.R. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2020, 245, 13-18.
[http://dx.doi.org/10.1016/j.ejogrb.2019.11.032] [PMID: 31812702]
[67]
Waldbaum, A.S.; Schwebke, J.R.; Paull, J.R.A.; Price, C.F.; Edmondson, S.R.; Castellarnau, A.; McCloud, P.; Kinghorn, G.R. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis. PLoS One, 2020, 15(5), e0232394.
[http://dx.doi.org/10.1371/journal.pone.0232394] [PMID: 32365097]
[68]
Schwebke, J.R.; Carter, B.A.; Waldbaum, A.S.; Agnew, K.J.; Paull, J.R.A.; Price, C.F.; Castellarnau, A.; McCloud, P.; Kinghorn, G.R. A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis. Eur. J. Obstet. Gynecol. Reprod. Biol. X, 2021, 10, 100121.
[http://dx.doi.org/10.1016/j.eurox.2021.100121] [PMID: 33537666]
[69]
Mendling, W.; Weissenbacher, E.R.; Gerber, S.; Prasauskas, V.; Grob, P. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch. Gynecol. Obstet., 2016, 293(3), 469-484.
[http://dx.doi.org/10.1007/s00404-015-3914-8] [PMID: 26506926]
[70]
Casa, V.; Noll, H.; Gonser, S.; Grob, P.; Graf, F.; Pohlig, G. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung, 2011, 52(9), 699-705.
[http://dx.doi.org/10.1055/s-0031-1299954] [PMID: 12404886]
[71]
Petersen, E.; Weissenbacher, E.; Hengst, P.; Spitzbart, H.; Wolfgang, W.; Wolff, F.; Dreher, E.; Ernst, U.; Casa, V.; Pohlig, G.; Graf, F.; Kaiser, R. Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung, 2011, 52(9), 706-715.
[http://dx.doi.org/10.1055/s-0031-1299955] [PMID: 12404887]
[72]
Gaspar, C.; Rolo, J.; Cerca, N.; Palmeira-de-Oliveira, R.; Martinez-de-Oliveira, J.; Palmeira-de-Oliveira, A. Dequalinium chloride effectively disrupts bacterial vaginosis (BV) Gardnerella spp. Biofilms. Pathogens, 2021, 10(3), 261.
[http://dx.doi.org/10.3390/pathogens10030261] [PMID: 33668706]
[73]
Weissenbacher, E.R.; Donders, G.; Unzeitig, V.; Martinez de Tejada, B.; Gerber, S.; Halaška, M.; Špaček, J. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol. Obstet. Invest., 2012, 73(1), 8-15.
[http://dx.doi.org/10.1159/000332398] [PMID: 22205034]
[74]
Antoni Vives, J.; Cancelo, M.J.; Losada, M.Á.; Doménech, A. Dequalinium chloride use in adult Spanish women with bacterial vaginosis: An observational study. J. Obstet. Gynaecol., 2022, 42(1), 103-109.
[http://dx.doi.org/10.1080/01443615.2020.1867966] [PMID: 33629634]
[75]
Surapaneni, S.; Akins, R.; Sobel, J.D. Recurrent bacterial vaginosis: An unmet therapeutic challenge. experience with a combination pharmacotherapy long-term suppressive regimen. Sex. Transm. Dis., 2021, 48(10), 761-765.
[http://dx.doi.org/10.1097/OLQ.0000000000001420] [PMID: 34110746]
[76]
Reichman, O.; Akins, R.; Sobel, J.D. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex. Transm. Dis., 2009, 36(11), 732-734.
[http://dx.doi.org/10.1097/OLQ.0b013e3181b08456] [PMID: 19704395]
[77]
Marrazzo, J.M.; Dombrowski, J.C.; Wierzbicki, M.R.; Perlowski, C.; Pontius, A.; Dithmer, D.; Schwebke, J. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: A randomized, single-blind, phase 2, controlled trial. Clin. Infect. Dis., 2019, 68(5), 803-809.
[http://dx.doi.org/10.1093/cid/ciy554] [PMID: 30184181]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy